image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.913
3.72 %
$ 75.7 M
Market Cap
-1.44
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TELA stock under the worst case scenario is HIDDEN Compared to the current market price of 1.91 USD, TELA Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TELA stock under the base case scenario is HIDDEN Compared to the current market price of 1.91 USD, TELA Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TELA stock under the best case scenario is HIDDEN Compared to the current market price of 1.91 USD, TELA Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TELA

image
$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.515 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
69.3 M REVENUE
18.56%
-34.1 M OPERATING INCOME
22.60%
-37.8 M NET INCOME
18.91%
-41.6 M OPERATING CASH FLOW
-1.81%
4.45 M INVESTING CASH FLOW
843.07%
43.1 M FINANCING CASH FLOW
-6.94%
18.5 M REVENUE
4.94%
-10.5 M OPERATING INCOME
-25.35%
-11.3 M NET INCOME
-22.33%
-9.72 M OPERATING CASH FLOW
-29.13%
138 K INVESTING CASH FLOW
172.63%
-116 K FINANCING CASH FLOW
-0.27%
Balance Sheet TELA Bio, Inc.
image
Current Assets 78.1 M
Cash & Short-Term Investments 52.7 M
Receivables 10.1 M
Other Current Assets 15.3 M
Non-Current Assets 8.5 M
Long-Term Investments 0
PP&E 4.08 M
Other Non-Current Assets 4.42 M
60.84 %11.66 %17.68 %4.71 %5.11 %Total Assets$86.6m
Current Liabilities 15.6 M
Accounts Payable 2.15 M
Short-Term Debt 545 K
Other Current Liabilities 12.9 M
Non-Current Liabilities 42.5 M
Long-Term Debt 41.1 M
Other Non-Current Liabilities 1.39 M
3.69 %22.21 %70.77 %Total Liabilities$58.1m
EFFICIENCY
Earnings Waterfall TELA Bio, Inc.
image
Revenue 69.3 M
Cost Of Revenue 22.8 M
Gross Profit 46.5 M
Operating Expenses 80.6 M
Operating Income -34.1 M
Other Expenses 3.73 M
Net Income -37.8 M
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)69m(23m)46m(81m)(34m)(4m)(38m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
67.08% GROSS MARGIN
67.08%
-49.23% OPERATING MARGIN
-49.23%
-54.60% NET MARGIN
-54.60%
-132.97% ROE
-132.97%
-43.71% ROA
-43.71%
-47.52% ROIC
-47.52%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis TELA Bio, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -37.8 M
Depreciation & Amortization 1.01 M
Capital Expenditures -989 K
Stock-Based Compensation 0
Change in Working Capital -4.87 M
Others -4.87 M
Free Cash Flow -42.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets TELA Bio, Inc.
image
Wall Street analysts predict an average 1-year price target for TELA of $10.9 , with forecasts ranging from a low of $8 to a high of $20 .
TELA Lowest Price Target Wall Street Target
8 USD 318.19%
TELA Average Price Target Wall Street Target
10.9 USD 467.55%
TELA Highest Price Target Wall Street Target
20 USD 945.48%
Price
Max Price Target
Min Price Target
Average Price Target
2020181816161414121210108866442200Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership TELA Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
2.02 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
410 K USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair Based on market research, inguinal hernia repair is the most common type of hernia repair Based on market research, inguinal hernia repair is the most common type of hernia repair globenewswire.com - 1 week ago
TELA Bio Appoints Jeffrey Blizard as President Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth globenewswire.com - 2 weeks ago
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. globenewswire.com - 3 weeks ago
TELA Bio, Inc. (TELA) Q1 2025 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Louisa Smith - The Gilmartin Group Antony Koblish - Co-founder, President & Chief Executive Office Roberto Cuca - Chief Operating Officer & Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Michael Sarcone - Jefferies David Turkaly - Citizens JMP Operator Good afternoon ladies and gentlemen and welcome to the TELA Bio First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode. seekingalpha.com - 1 month ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 6,600 shares of its common stock to twelve newly-hired employees, with a grant date of May 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com - 1 month ago
TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.23 per share a year ago. zacks.com - 1 month ago
TELA Bio to Announce First Quarter 2025 Financial Results MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. globenewswire.com - 1 month ago
TELA Bio, Inc. (TELA) Q4 2024 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Greg Chodaczek - The Gilmartin Group Antony Koblish - Co-founder, President and Chief Executive Office Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity David Turkaly - Citizens Matt O'Brien - Piper Sandler Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 2 months ago
TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.53 per share a year ago. zacks.com - 2 months ago
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 2 months ago
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. globenewswire.com - 3 months ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com - 4 months ago
8. Profile Summary

TELA Bio, Inc. TELA

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 75.7 M
Dividend Yield 0.00%
Description TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Contact 1 Great Valley Parkway, Malvern, PA, 19355 https://www.telabio.com
IPO Date Nov. 8, 2019
Employees 209
Officers Ms. Megan Smeykal Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer Ms. Jennifer Lou Armstrong Senior Vice President of Human Resources Louisa Smith Investor Relations Contact Officer Mr. Paul Talmo Chief Technology Officer Mr. Gregory A. Firestone Chief Commercial Officer Mr. Michael Leonard Senior Vice President of Technical Operations Mr. Antony Koblish Co-founder, President, Chief Executive Officer & Director Mr. Roberto E. Cuca J.D. Chief Financial Officer & Chief Operating Officer Mr. D. Taylor Ocasio General Counsel & Corporate Secretary Mr. Peter C. Murphy Chief Commercial Officer